


First-line treatment for mSCLC in the elderly (age 80)

An otherwise healthy 80-year-old patient presents with low tumor burden, asymptomatic, metastatic PWT squamous cell carcinoma of the lung. What is your preferred first-line treatment regimen?



EDITOR'S COMMENTS

In the older patient — in this case, age 80 — there is a similar split between the 3 previously discussed carboplatin-based regimens. Interestingly, although Dr Wakelee sticks with carboplatin/gemcitabine, Dr Ramalingam abandons carboplatin/paclitaxel in favor of carboplatin/*nab* paclitaxel. His rationale for the switch is 2-fold, citing both the potential for less toxicity and data from the seminal trial showing a substantial survival benefit in favor of *nab* paclitaxel in patients older than age 70.

SELECT REFERENCES WITH LINKS

Socinski MA et al. **Safety and efficacy of weekly *nab*[®]-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.** *Ann Oncol* 2013;24(2):314-21. [Abstract](#)

Socinski MA et al. **Weekly *nab*-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial.** *J Clin Oncol* 2012;30(17):2055-62. [Abstract](#)